Testing effectiveness (Phase 2)Looking for participantsNCT06852963
What this trial is testing
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
Who this might be right for
Retinitis Pigmentosa 11Retinal DegenerationRetinal Disease+2 more
PYC Therapeutics 16